Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Hailide: PPS filament products have not yet been involved in the field of humanoid robots. Hailide said on the interactive platform on December 13th that the company has been deeply involved in the field of materials for many years, and with the continuous investment in research and development, the commercialization of PPS filament has been realized. At present, the product has not yet been involved in the field of humanoid robots. In the future, the company will strive to gradually realize mass production applications in related emerging fields, and is full of confidence in this.Liao Min held video talks with the heads of sovereign credit rating teams of international credit rating companies. Recently, Vice Minister of Finance Liao Min held video talks with Mary Duron, global head of Moody's Sovereignty and Local Government Risk Department, and Roberto Xifeng-Arevalo, global head of Standard & Poor's Sovereignty Rating Team, respectively, to introduce the latest incremental policies of the China government, and exchanged views with each other on issues such as government debt management, fiscal sustainability, fiscal policy supporting the high-quality development of the real economy, and fiscal and taxation system reform. Both Moody's and Standard & Poor's said that the introduction of the Ministry of Finance was comprehensive and frank, which was very helpful for them to deepen their understanding of the macro policies of the China government, and they looked forward to more exchanges between the two sides. (Ministry of Finance)
On the 13th, glass fell by 2.14%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract glass closed at 2505, up or down by -2.14%, with a turnover of 671,300 lots. The position data showed that the top 20 seats were clear, and the difference position was 46,081 lots. The total turnover of glass futures contracts was 999,900 lots, an increase of 189,100 lots over the previous day. The first 20 seats in the contract held 565,600 lots, a decrease of 12,000 lots from the previous day. The short positions in the top 20 seats of the contract were 661,500 lots, a decrease of 13,600 lots from the previous day. (Sina Futures)Tencent set up a management consulting company in Shenzhen with a registered capital of 5 million yuan. According to Tianyancha App, recently, Shenzhen Xintengjia Management Consulting Co., Ltd. was established with Jin Fang as its legal representative and a registered capital of 5 million yuan. Its business scope includes enterprise management consulting, human resources services, property management, hotel management and software development. According to shareholder information, the company is wholly owned by Shenzhen Tencent Digital Technology Co., Ltd..The head of the region said that the Russian attack on the key infrastructure in the Ivano-Frankov region was the biggest attack on the region so far.
Saudi institutions are optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology. Ekta Torani, chief investment officer of Saudi KBW Venture Capital Company, recently said in Abu Dhabi, United Arab Emirates that with the increasingly close economic and trade ties between the Gulf region and China, the institution is optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology.Zhengzhou Investment Holding Company increased its capital to 7.78 billion yuan, with an increase of about 121%. Tianyancha App shows that Zhengzhou Investment Holding Co., Ltd. has undergone industrial and commercial changes recently, adding Zhengzhou Development Investment Group Co., Ltd. as a shareholder, and its registered capital has increased from about 3.53 billion yuan to about 7.78 billion yuan, with an increase of about 121%. At the same time, many senior executives have changed. Zhengzhou Investment Holding Co., Ltd. was established in October 2005, and its legal representative is Yu Jianwei. Its business scope covers state-owned assets investment and management, real estate development and sales, and house leasing. Now Zhengzhou Zhongrongchuang Industrial Investment Co., Ltd. and the above-mentioned newly-added shareholders jointly hold shares.Vegetable oil fell by 1.90% on the 13th, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract vegetable oil closed at 2,505, up or down by -1.90%, with a turnover of 535,800 lots. The position data showed that the top 20 seats were clear, and the difference position was 21,545 lots. The total turnover of vegetable oil futures contracts was 593,700 lots, a decrease of 112,100 lots from the previous day. The first 20 seats in the contract held 232,900 lots, a decrease of 3,819 lots from the previous day. The short positions in the top 20 seats of the contract were 254,200 lots, an increase of 687 lots over the previous day. (Sina Futures)
Strategy guide 12-14
Strategy guide 12-14